Abstract
Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 411-413 |
| Number of pages | 3 |
| Journal | Ophthalmologica |
| Volume | 223 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2009 Oct 1 |
Fingerprint
Keywords
- Bevacizumab
- Choroidal metastasis
- Erlotinib
- Non-small-cell lung cancer
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
Cite this
Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy. / Kim, Seong-Woo; Kim, Myung Jin; Huh, Kuhl; Oh, Jae Ryung.
In: Ophthalmologica, Vol. 223, No. 6, 01.10.2009, p. 411-413.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy
AU - Kim, Seong-Woo
AU - Kim, Myung Jin
AU - Huh, Kuhl
AU - Oh, Jae Ryung
PY - 2009/10/1
Y1 - 2009/10/1
N2 - Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.
AB - Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography (FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC.
KW - Bevacizumab
KW - Choroidal metastasis
KW - Erlotinib
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=67651006008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651006008&partnerID=8YFLogxK
U2 - 10.1159/000229307
DO - 10.1159/000229307
M3 - Article
C2 - 19628953
AN - SCOPUS:67651006008
VL - 223
SP - 411
EP - 413
JO - Ophthalmologica
JF - Ophthalmologica
SN - 0030-3755
IS - 6
ER -